Cargando…
Phase IIb trial comparing two concurrent cisplatin schedules in locally advanced head and neck cancer
BACKGROUND: Concurrent chemoradiation with 3 weekly cisplatin (100 mg/m(2)) is the standard of care for locally advanced head and neck cancer. However, this regimen has been shown to be associated with lesser compliance and higher toxicities. Hence, there is a need to explore alternative concurrent...
Autores principales: | Nair, Lekha Madhavan, Kumar, R. Rejnish, Thomachan, Kainickal Cessal, Rafi, Malu, George, Preethi Sara, Krishna, K. M. Jagathnath, Ramadas, Kunnambath |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5506812/ https://www.ncbi.nlm.nih.gov/pubmed/28702409 http://dx.doi.org/10.4103/2278-330X.208840 |
Ejemplares similares
-
Treatment Outcomes of Adenoid Cystic Carcinomas of the Head and Neck Region—A Single-Institution Experience
por: Rafi, Malu, et al.
Publicado: (2022) -
Treatment outcomes and prognostic factors of esthesioneuroblastoma—a retrospective study from South India
por: Nair, Lekha Madhavan, et al.
Publicado: (2023) -
Epstein–Barr virus dynamics and its prognostic impact on nasopharyngeal cancers in a non-endemic region
por: Ganapathi, Rajitha, et al.
Publicado: (2022) -
Outcomes of organ preservation treatment in advanced laryngeal carcinoma: A retrospective analysis from a single institution
por: Fasaludeen, Afsar, et al.
Publicado: (2022) -
Clinical Profile and Treatment Outcomes in Patients Treated with Intensity-Modulated Radiotherapy (IMRT) for Carcinoma Nasopharynx: A Retrospective Analysis
por: Nazeer, Farida, et al.
Publicado: (2021)